Research Article
Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
| Patients | 50,000 |
| Maximum treatment period with belimumab | 10 years |
| Maximum effect related to belimumab | Lifetime |
| Subgroup | Patient with low complement and anti-dsDNA |
| Responder rule |
Reduction SELENA-SLEDAI ≥ 4 at 24th week |
| Natural history model | JH-AMS* forced in, involvement removed |
| Long term disease activity model | Adjusted natural history models (NHM) |
| One-year steroid model | NHM |
|
|
*Johns Hopkins University (JH) Adjusted Mean SLEDAI (AMS).
|